Keyphrases
Metabolism System
100%
Skeletal System
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Sodium-glucose Cotransporter
100%
Mineral Metabolism
100%
Type 2 Diabetes Mellitus (T2DM)
66%
Sweet
66%
Blood Glucose
50%
Chronic Kidney Disease
50%
Diabetic Kidney Disease
33%
Long-term Complications
33%
Hypercalciuria
33%
Renal Tubule
33%
Serum Phosphorus
16%
Clinical Development
16%
Diabetes Management
16%
Total Loss
16%
Oral Drugs
16%
Hyperphosphatemia
16%
Reabsorption
16%
Urinary Phosphate
16%
Proximal Tubule
16%
Glucose-lowering Drugs
16%
Nonsense mutation
16%
Glucosuria
16%
Growth Retardation
16%
Global Public Health
16%
Urinary Glucose Excretion
16%
Renal System
16%
Bone Demineralization
16%
Nephroprotective
16%
Fracture Risk
16%
Intact Parathyroid Hormone (iPTH)
16%
Bone Remodeling
16%
Phosphorus Loss
16%
Type 2 Diabetic Patients
16%
Fibroblast Growth Factor 23 (FGF23)
16%
Early Phase Clinical Trials
16%
Longitudinal Effects
16%
Lumen
16%
Mechanistic Insight
16%
Public Health Risk
16%
Cardiovascular System
16%
Bone Metabolism
16%
End-stage Renal Disease
16%
Capillary
16%
Cardiovascular Outcomes
16%
Hyperglycemia
16%
Mouse Model
16%
Risk Reduction
16%
New Therapeutic Strategies
16%
Medicine and Dentistry
Sodium Glucose Cotransporter 2
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Skeletal System
100%
Mineral Metabolism
100%
Chronic Kidney Disease
50%
Blood Glucose
50%
Type 2 Diabetes
33%
Hypercalciuria
33%
Glucosuria
33%
Maturity Onset Diabetes of the Young
33%
Urinary System
33%
Renal System
16%
Osteoplasty
16%
Bone Decalcification
16%
Capillary
16%
Nonsense Mutation
16%
Renal Tubule
16%
End Stage Renal Disease
16%
Diabetic Nephropathy
16%
Renal Protection
16%
Hyperphosphatemia
16%
Hyperglycemia
16%
Patient with Type 2 Diabetes
16%
Cardiovascular System
16%
Growth Retardation
16%
Public Health
16%
Diabetes
16%
Clinical Trial
16%
Fibroblast Growth Factor 23
16%
Parathyroid Hormone
16%
Cardiovascular System
16%
Bone Remodeling
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sodium Glucose Cotransporter 2 Inhibitor
100%
Sodium Glucose Cotransporter 2
100%
Chronic Kidney Failure
50%
Non Insulin Dependent Diabetes Mellitus
50%
Glucosuria
33%
Hypercalciuria
33%
Mouse Model
16%
Bone Demineralization
16%
Growth Retardation
16%
End Stage Renal Disease
16%
Clinical Trial
16%
Fibroblast Growth Factor 23
16%
Hyperphosphatemia
16%
Parathyroid Hormone
16%
Hyperglycemia
16%
Diabetic Nephropathy
16%